Successful development of a vaccine against HIV will likely require the induction of both antibody and/or cellular immune responses sufficient to prevent infection or disease respectively following infectious challenge. Recent work analyzing HIV specific antibody responses from infected individuals has shown that broadly neutralizing antibodies are directed at several sites on the HIV Env. Moreover, several of these antibodies have unique characteristics such as a high rate of somatic mutation and/or long CDRH3 regions. Thus, improving antigen design and understanding the in vivo mechanisms that control the maturation of the B cell response with various vaccines should facilitate development of a successful HIV vaccine. The data obtained over this past year have shown the following; 1. A comparative analysis of adjuvants and formulation was recently completed in NHP using HIV Env protein. This study focused on two clinically approved adjuvants ( alum and MF-59) with or without TLR 4 or TLR 7 ligands as additional immune stimulators. The data generated so far show that MF-59 induces more potent humoral and cellular immunity than alum when given with HIV Env protein. Combining alum with a TLR 7 ligand strongly enhanced immunity compared to alum alone. By contrast, adding TLR 4 or TLR 7 ligands to MF 59 did increase immunity compared to alum alone. In terms of T cell immunity, MF 59 induced a mixed Th1 and Th2 cytokine response. HIV Env specific B cells were isolated from all NHP that had been immunized with these 8 different adjuvants and next generation sequencing performed. Data was analyzed for the extent of somatic mutation, length of CDRH3 regions and Vh gene family usage. 2. In collaboration with Dr. Malcolm Martin, we analyzed the extent of somatic mutation, length of CDRH3 regions and Vh gene family usage. of the HIV Env B cell response following infection with SHIV Ad8 in NHP. This is a pathogenic virus that causes several characteristics associated with HIV infection in humans and provides a model for understanding how broadly neutralizing antibodies are developed. 3. Adjuvant Development: A key feature of adjuvants are to optimize the immune response by providing innate stimulation at the site of T and B cell priming ( draining lymph node) and limit systemic innate activation to prevent inflammation and toxicity. Moreover, by improving the formulation of adjuvants to persist longer at the site of immune priming, this will lead to improved generation of T cell and antibody responses. Using novel synthetic polymers and agonists which activate toll like receptor 7 and 8 ligands we performed a series of studies in mice that assessed the physiochemical parameters of the adjuvant delivery system and defined the in vivo immune mechanisms by which they influenced innate and adaptive immunity

Project Start
Project End
Budget Start
Budget End
Support Year
13
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Niaid Extramural Activities
Department
Type
DUNS #
City
State
Country
Zip Code
Liang, Frank; Lindgren, Gustaf; Sandgren, Kerrie J et al. (2017) Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake. Sci Transl Med 9:
Francica, Joseph R; Lynn, Geoffrey M; Laga, Richard et al. (2016) Thermoresponsive Polymer Nanoparticles Co-deliver RSV F Trimers with a TLR-7/8 Adjuvant. Bioconjug Chem 27:2372-2385
Moody, M Anthony; Santra, Sampa; Vandergrift, Nathan A et al. (2014) Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques. J Virol 88:3329-39
Feng, Yu; Forsell, Mattias N E; Flynn, Barbara et al. (2013) Chemical cross-linking of HIV-1 Env for direct TLR7/8 ligand conjugation compromises recognition of conserved antigenic determinants. Virology 446:56-65
Quinn, Kylie M; Yamamoto, Ayako; Costa, Andreia et al. (2013) Coadministration of polyinosinic:polycytidylic acid and immunostimulatory complexes modifies antigen processing in dendritic cell subsets and enhances HIV gag-specific T cell immunity. J Immunol 191:5085-96
Quinn, Kylie M; Da Costa, Andreia; Yamamoto, Ayako et al. (2013) Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J Immunol 190:2720-35
Park, Haesun; Adamson, Lauren; Ha, Tae et al. (2013) Polyinosinic-polycytidylic acid is the most effective TLR adjuvant for SIV Gag protein-induced T cell responses in nonhuman primates. J Immunol 190:4103-15
Johnson, Matthew J; Petrovas, Constantinos; Yamamoto, Takuya et al. (2012) Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity. J Immunol 188:6109-18
Petrovas, Constantinos; Yamamoto, Takuya; Gerner, Michael Y et al. (2012) CD4 T follicular helper cell dynamics during SIV infection. J Clin Invest 122:3281-94
Gujer, Cornelia; Sundling, Christopher; Seder, Robert A et al. (2011) Human and rhesus plasmacytoid dendritic cell and B-cell responses to Toll-like receptor stimulation. Immunology 134:257-69

Showing the most recent 10 out of 21 publications